Keeping tabs on Covid-19: BioNTech buys GMP-certified facility to boost vaccine…
The Pharma Data
SEPTEMBER 18, 2020
BioNTech plans to manufacture additional therapeutic and vaccine drug candidates at the plant, such as other mRNA vaccines, antibody and cell and gene therapy candidates to support the development of its diversified cancer and infectious disease product pipeline.
Let's personalize your content